Removal from the plasma of the free and esterified forms of cholesterol and transfer of lipids to HDL in type 2 diabetes mellitus patients

Lipids in Health and Disease

Antonio C Lerario²  Bernardo L Wajchenberg²  Marina P Bertato²  Raul C Maranhão¹  Carolina P Oliveira² 

[1] Instituto do Coração do HC-FMUSP, Av Dr. Enéas de Carvalho Aguiar, 44, CEP- 05423-000, São Paulo, SP, Brazil;Endocrinology Service of the Medical School Hospital, University of Sao Paulo, São Paulo, Brazil

关键词: Emulsion;    Nanoparticles;    Lipid transfer;    High density lipoprotein;    Low density lipoprotein;    Lipoprotein;    Type 2 diabetes mellitus;   

Others  :  1160295
DOI  :  10.1186/1476-511X-11-65

 received in 2012-02-03, accepted in 2012-04-11,  发布年份 2012

【 摘 要 】

Background

The aim was to investigate new markers for type 2 diabetes (T2DM) dyslipidemia related with LDL and HDL metabolism. Removal from plasma of free and esterified cholesterol transported in LDL and the transfer of lipids to HDL are important aspects of the lipoprotein intravascular metabolism. The plasma kinetics (fractional clearance rate, FCR) and transfers of lipids to HDL were explored in T2DM patients and controls, using as tool a nanoemulsion that mimics LDL lipid structure (LDE).

Results

¹⁴C- cholesteryl ester FCR of the nanoemulsion was greater in T2DM than in controls (0.07 ± 0.02 vs. 0.05 ± 0.01 h^-1, p = 0.02) indicating that LDE was removed faster, but FCR ³ H- cholesterol was equal in both groups. Esterification rates of LDE free-cholesterol were equal. Cholesteryl ester and triglyceride transfer from LDE to HDL was greater in T2DM (4.2 ± 0.8 vs. 3.5 ± 0.7%, p = 0.03 and 6.8 ± 1.6% vs. 5.0 ± 1.1, p = 0.03, respectively). Phospholipid and free cholesterol transfers were not different.

Conclusions

The kinetics of free and esterified cholesterol tended to be independent in T2DM patients and the lipid transfers to HDL were also disturbed. These novel findings may be related with pathophysiological mechanisms of diabetic macrovascular disease.

【 授权许可】

   
2012 Oliveira et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1 .

Figure 2 .

【 参考文献 】

• [1]Chahil TJ, Ginsberg HN: Diabetic Dyslipidemia. Endocrinol Metab Clin N Am 2006, 35:496-510.
• [2]Ikonen E: Cellular cholesterol trafficking and compartmentalization. Nature rev 2008, 9:125-138.
• [3]Jin W, Marchadier D, Rader DJ: Lipases and HDL metabolism. Trends Endocrinol Metab 2002, 13:174-178.
• [4]Duvillard L, Florentin E, Lizard G, Petit JM, Galland F, Monier S, Gambert P, Verges : Cell surface expression of LDL receptor is decreased in type 2 diabetic patients and is normalized by insulin therapy. Diabetes Care 2003, 26:1540-1544.
• [5]Wade DP, Knight BL, Soutar AK: Hormonal regulation of low-density lipoprotein (LDL) receptor activity in human hepatoma Hep G2 cells. Insulin increases LDL receptor activity and diminishes its suppression by exogenous LDL. Eur J Biochem 1988, 174:213-218.
• [6]Wade DP, Knight BL, Soutar AK: Regulation of low-density-lipoprotein receptor mRNA by insulin in human hepatoma Hep G2 cells. Eur J Biochem 1989, 181:727-731.
• [7]Selby JV, Austim MA, Newmam B, et al.: LDL subclass phenotypes and the insulin resistance syndrome in women. Circulation 1993, 88:381-387.
• [8]Feingold KR, Grunfeld C, Pang M, Doerrler W, Krauss RM: LDL subclass phenotypes and triglyceride metabolism in non-insulin dependent diabetes. Arterioscler Thromb 1992, 12:1496-1502.
• [9]Younis N, Sharma R, Soran H, Charlton-Menys V, Elseweidy M, Durrington PN: Glycation as atherogenic modification of LDL. Curr Opin Lipidol 2008, 19:378-384.
• [10]Jeppesen J, Hein HO, Suadicami P, Gyntelberg F: Relation of high TG- low HDL cholestherol and LDL cholestherol to the incidence of ischemic heart disease. An 8 year follow up in the Copenhagem Male study. Arterioescler Thromb Vasc Biol 1997, 17:1114-1120.
• [11]Howard BV, Robbins DC, Sievers ML, Lee ET, et al.: LDL cholestherol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL. The Strong Heart Study. Arterioscler Tromb Vasc Biol 2000, 20:830-835.
• [12]Stamler J, Vacaro O, Neaton JD, Wentworth D: Diabetes, other risk factors and 12 years cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993, 16:434-444.
• [13]Turner RC, Millns H, Neil HA, Stratton IM, Manley SE, et al.: Risk factor for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Study (UKPDS: 23). BMJ 1998, 316:823-828.
• [14]Haffner SM, Letho S, Ronnemaa T, Pyrola K, Laskso M: Mortality from coronary heart disease in subjects with type 2 diabetes and in non diabetic subjects with and without prior coronary myocardial infarction. N Engl J Med 1998, 339:229-234.
• [15]Almdal T, Scharling H, Jensen JS, Vestergaard H: The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke and death: a population study of 13,000 men and women with 20 years of follow up. Arch Intern Med 2004, 164:1422-1426.
• [16]Tan KC: Reverse cholesterol transport in type 2 diabetes mellitus. Diabetes Obes Metab 2009, 11:534-543.
• [17]Tall AR: The effects of cholesterol ester transfer protein inhibition on cholesterol efflux. Am J Cardiol 2009, 104:39E-45E.
• [18]Bagdade JD, Kelley DE, Henry RR, Eckel RH, Ritter MC: Effects of multiple daily insulin injections and intraperitoneal insulin therapy on cholesteryl ester transfer and lipoprotein lipases activities in NIDDM. Diabetes 1997, 46:414-420.
• [19]Borggreve SE, Vries R, Dullaart RPF: Alterations in high- density lipoprotein metabolism and reverse cholesterol transport in insulin resistance and type 2 diabetes mellitus: role of lipolytic enzymes, lecithin:cholesterol acyltransferase and lipid transfer proteins. Eur J Clin Invest 2003, 33:1051-1069.
• [20]Stein O: Athero protective mechanism of HDL. Atherosclerosis 1999, 144:285-301.
• [21]Maranhão RC, Garicochea B, Silva EL, et al.: Plasma kinetics andbiodistribution of a lipid emulsion resembling low-density lipoprotein in patients with acute leukemia. Cancer Res 1994, 54:4660-4666.
• [22]Maranhão RC, Cesar TB, Pedroso-Mariani SR, Hirata MH, Mesquita CH: Metabolic behavior in rats of a nonprotein microemulsion resembling low-density lipoprotein. Lipids 1993, 28:691-696.
• [23]Maranhão RC, Roland IA, Toffoletto O, et al.: Plasma kinetic behavior in hyperlipidemic subjects of a lipidic microemulsion that binds to low density lipoprotein receptors. Lipids 1997, 32:627-633.
• [24]Santos RD, Chacra AP, Morikawa A, Vinagre CC, Maranhão RC: Plasma kinetics of free and esterified cholesterol in familial hypercholesterolemia: effects of simvastatin. Lipids 2005, 40:737-743.
• [25]Vinagre CG, Ficker ES, Finazzo C, et al.: Enhanced removal from the plasma of LDL-like nanoemulsion cholesteryl ester in trained men compared with sedentary healthy men. J Appl Physiol 2007, 103:1166-1171.
• [26]Santos RD, Hueb W, Oliveira AA, Ramires JAF, Maranhão RC: Plasma kinetics of cholesterol-rich emulsions in subjects with or without coronary artery disease. J Lipid Res 2003, 44:464-469.
• [27]Couto RD, Dallan LA, Lisboa LA, Mesquita CH, Vinagre CG, Maranhao RC: Deposition of free cholesterol in the blood vessels of patients with coronary artery disease: a possible novel mechanism for atherogenesis. Lipids 2007, 42:411-418.
• [28]Collins R, Armitage J, Parish S, Sleigh P, Peto R: MRC/BHF Heart Protection Study of cholesterol - lowering with simvastatin in 5963 people with diabetes: a randomized placebo- controlled trial. Lancet 2003, 361:2005-2016.
• [29]Sheperd J, Barter P, Carmena R, et al.: Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: The Treating to New Targets (TNT) study. Diabetes Care 2006, 29:1220-1226.
• [30]Lo Prete AC, Dina CH, Azevedo CH, et al.: In vitro simultaneous transfer of lipids to HDL in coronary artery disease and in statin treatment. Lipids 2009, 44:917-924.
• [31]Zhou G, Myers R, Li Y, et al.: Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001, 108:1162-1174.
• [32]Hardie DG, Carling D: The AMP- activated protein kinase-fuel gauge of the mammalian cell? Eur J Biochem 1997, 246:259-273.
• [33]Kemp BE, Mitchelhill KI, Stapleton D, Michell BJ, Chen ZP, Witters LA: Dealing with energy demand: the AMP-activated protein kinase. Trends Biochem Sci 1999, 24:22-25.
• [34]Mahley RW, Innerarity TL, Rall SC, Weisgraber KH: Plasma lipoproteins: apolipoprotein structure and function. J Lipid Res 1984, 25(12):1277-1294.
• [35]Rhainds D, Brodeur M, Lapointe J, Charpentier D, Falstrault L, Brissette L: The role of human and mouse hepatic Scavenger Receptor Class B Type I (SR-BI) in the selective uptake of low density lipoprotein- cholesteryl esters. Biochemistry 2003, 42:7527-7538.
• [36]Brissette L, Charest M, Falstrault L, et al.: Selective uptake of cholesteryl esters from various classes of lipoproteins by HepG2 cells. Biochem Cell Biol 1999, 77:157-163.
• [37]Gylling H, Miettinen TA: Cholesterol absorption Synthesis and LDL metabolism in NIDDM. Diabetes Care 1997, 20:90-95.
• [38]Kissebah AH, Alfarsi S, Evans DJ, Adams PW: Plasma low density lipoprotein transport kinetics in Noninsulin-dependent diabetes mellitus. J Clin Invest 1982, 71:655-667.
• [39]Kissebah AH: Low density lipoprotein Metabolism in Non-insulin Dependent Diabetes Mellitus. Diabetes/Metabol Rev 1987, 3:619-651.
• [40]Chan DC, Barret PHR, Watts GF: Recent studies of lipoprotein kinetics in the metabolic syndrome and related disorders. Curr Opin Lipidol 2006, 17:28-36.
• [41]Maranhao RC, Freitas FR, Strunz CM, Santos RD, Mansur AJ, Mansur AP: Lipid transfers to HDL are predictors of precocious clinical coronary heart disease. Clin Chim Acta 2012, 413:502-505.
• [42]Puk CG, Bocchi EA, Lo Prete AC, Ferreira SM, Stolf NA, Maranhão RC: Transfer of cholesterol and other lipids from a lipid nanoemulsion to high-density lipoprotein in heart transplant patients. J Heart Lung Transplant 2009, 28(10):1075-1080.
• [43]Feitosa-Filho GS, Seydell Tde M, Feitosa AC, Maranhão RC, Ramires JA: Lipid transfer to HDL in type-2 diabetic patients: associations with microalbuminuria, statin, and insulin. Arq Bras Cardiol 2009, 92(2):94-106.
• [44]da Silva JL, Vinagre CG, Morikawa AT, Alves MJ, Mesquita CH, Maranhão RC: Resistance training changes LDL metabolism in normolipidemic subjects: a study with a nanoemulsion mimetic of LDL. Atherosclerosis 2011, 219(2):532-537.
• [45]Marchese SRM, Mesquita CH, Cunha IL: Anacomp program application to calculate 137 C transfer rates in marine organism and dose in man. J Radioan Nucl Chem 1998, 232:233-236.
• [46]Guidance for industry: Bioanalytical method validation. US Department of Health and Human Services FDA: Center of Drug Evaluation and Research (CDER) and Center for Veterinary Medicine (CVM), USA; 2001.
• [47]Sowby FS: Radiation protection. In Limits for intakes of radionuclides by workers. ICRP publication 30. Part I. Pergamond, Oxford; 1984:30.